An Interventional, Open Label, and Randomized Controlled Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Opioid-naive Patients With Moderate to Severe Cancer Pain
Latest Information Update: 20 Mar 2020
Price :
$35 *
At a glance
- Drugs Oxycodone (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors Taiwan Mundipharma Pharmaceuticals
- 16 Mar 2020 Status changed from recruiting to completed.
- 08 Jun 2017 New trial record